Immucell vs Neogen: revenue, profit, margins and growth compared
Immucell brought in $27.6M of revenue in fiscal 2025, Neogen $870.4M in fiscal 2026. Revenue changed by +4.3% at Immucell and -2.7% at Neogen on the year before, so Immucell grew faster. Immucell kept -3.8% of its revenue as net profit, Neogen -0.9%. Free cash flow was $1.2M at Immucell and $31.9M at Neogen.
Fiscal years as each company reports them; the two may end in different months.
Questions about Immucell and Neogen
Which is bigger by revenue, Immucell or Neogen?
Neogen is bigger by revenue: $870.4M in fiscal 2026, against $27.6M for Immucell in fiscal 2025.
Which keeps more of its revenue as profit, Immucell or Neogen?
Immucell had a net margin of -3.8% in fiscal 2025; Neogen had -0.9% in fiscal 2026.
Which grew revenue faster, Immucell or Neogen?
In their latest fiscal years revenue changed by +4.3% at Immucell and -2.7% at Neogen.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.